Zobrazeno 1 - 10
of 91
pro vyhledávání: '"Colin A. Miller"'
Autor:
Sun Woo Sophie Kang, Rory P. Cunningham, Colin B. Miller, Lauryn A. Brown, Constance M. Cultraro, Adam Harned, Kedar Narayan, Jonathan Hernandez, Lisa M. Jenkins, Alexei Lobanov, Maggie Cam, Natalie Porat-Shliom
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-17 (2024)
Abstract In the liver, mitochondria are exposed to different concentrations of nutrients due to their spatial positioning across the periportal and pericentral axis. How the mitochondria sense and integrate these signals to respond and maintain homeo
Externí odkaz:
https://doaj.org/article/2c66b12c825b487c840eeb96a8179b89
Autor:
Colin T. Shearn, Aimee L. Anderson, Colin G. Miller, Reed C. Noyd, Michael W. Devereaux, Nata Balasubramaniyan, David J. Orlicky, Edward E. Schmidt, Ronald J. Sokol
Publikováno v:
Hepatology Communications, Vol 7, Iss 1, Pp e0020-e0020 (2023)
Background and Aims:. Cholestatic liver diseases, including primary sclerosing cholangitis, are characterized by periportal inflammation with progression to hepatic fibrosis and ultimately cirrhosis. We recently reported that the thioredoxin antioxid
Externí odkaz:
https://doaj.org/article/65bdde1608a44f779026293984db4f20
Autor:
Colin G. Miller, Henning Grønbæk, Irene Virgolini, Andreas Kjaer, Pierre Terve, Shadfar Bahri, Peter Iversen, Hanna Svirydenka, Thomas Rohban, Sandy McEwan
Publikováno v:
EJNMMI Research, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract Background 68Ga-satoreotide trizoxetan is a novel somatostatin receptor antagonist exhibiting higher tumour-to-background ratios and sensitivity compared to 68Ga-DOTATOC. This randomised, 2 × 3 factorial, phase II study aimed to confirm the
Externí odkaz:
https://doaj.org/article/4c8b1bb0808c480fadaf97e8afe9d6a7
Autor:
Colin T Shearn, Aimee L Anderson, Michael W Devereux, David J Orlicky, Cole Michel, Dennis R Petersen, Colin G Miller, Sanjiv Harpavat, Edward E Schmidt, Ronald J Sokol
Publikováno v:
PLoS ONE, Vol 17, Iss 11, p e0276879 (2022)
Inflammatory cholestatic liver diseases, including Primary Sclerosing Cholangitis (PSC), are characterized by periportal inflammation with progression to cirrhosis. The objective of this study was to examine interactions between oxidative stress and
Externí odkaz:
https://doaj.org/article/ce15a1ec4a624b35aa47d9ec04c0050d
Autor:
Deepti Talwar, Colin G. Miller, Justus Grossmann, Lukasz Szyrwiel, Torsten Schwecke, Vadim Demichev, Ana-Matea Mikecin Drazic, Anand Mayakonda, Pavlo Lutsik, Carmen Veith, Michael D. Milsom, Karin Müller-Decker, Michael Mülleder, Markus Ralser, Tobias P. Dick
Publikováno v:
Nature Metabolism. 5:660-676
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is known to contain an active-site cysteine residue undergoing oxidation in response to hydrogen peroxide, leading to rapid inactivation of the enzyme. Here we show that human and mouse cells expressin
Autor:
Justin R. Prigge, Lucia Coppo, Sebastin S. Martin, Fernando Ogata, Colin G. Miller, Michael D. Bruschwein, David J. Orlicky, Colin T. Shearn, Jean A. Kundert, Julia Lytchier, Alix E. Herr, Åse Mattsson, Matthew P. Taylor, Tomas N. Gustafsson, Elias S.J. Arnér, Arne Holmgren, Edward E. Schmidt
Publikováno v:
Cell Reports, Vol 19, Iss 13, Pp 2771-2781 (2017)
Energetic nutrients are oxidized to sustain high intracellular NADPH/NADP+ ratios. NADPH-dependent reduction of thioredoxin-1 (Trx1) disulfide and glutathione disulfide by thioredoxin reductase-1 (TrxR1) and glutathione reductase (Gsr), respectively,
Externí odkaz:
https://doaj.org/article/608638e94517493f8c9dd7af8d0965f9
Autor:
Colin G. Miller, Jean A. Kundert, Justin R. Prigge, Julie A. Amato, Allison E. Perez, Lucia Coppo, Gabrielle N. Rizzo, Michael P. Kavanaugh, David J. Orlicky, Colin T. Shearn, Edward E. Schmidt
Publikováno v:
Antioxidants, Vol 10, Iss 3, p 359 (2021)
Cellular oxidants are primarily managed by the thioredoxin reductase-1 (TrxR1)- and glutathione reductase (Gsr)-driven antioxidant systems. In mice having hepatocyte-specific co-disruption of TrxR1 and Gsr (TrxR1/Gsr-null livers), methionine cataboli
Externí odkaz:
https://doaj.org/article/98510a8d188d4921848458dea2409ac7
Autor:
Thomas Rohban, Henning Grønbæk, Colin G. Miller, Sandy McEwan, Andreas Kjaer, Pierre Terve, Hanna Svirydenka, Irene Virgolini, Shadfar Bahri, Peter Iversen
Publikováno v:
EJNMMI Research, Vol 11, Iss 1, Pp 1-11 (2021)
EJNMMI Research
Miller, C G, Grønbæk, H, Virgolini, I, Kjaer, A, Terve, P, Bahri, S, Iversen, P, Svirydenka, H, Rohban, T & McEwan, S 2021, ' A novel read methodology to evaluate the optimal dose of 68 Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours : a phase II clinical trial ', EJNMMI Research, vol. 11, no. 1, 84, pp. 1-11 . https://doi.org/10.1186/s13550-021-00819-1
Miller, C G, Grønbæk, H, Virgolini, I, Kjaer, A, Terve, P, Bahri, S, Iversen, P, Svirydenka, H, Rohban, T & McEwan, S 2021, ' A novel read methodology to evaluate the optimal dose of 68 Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours : a phase II clinical trial ', EJNMMI research, vol. 11, no. 84, 84 . https://doi.org/10.1186/s13550-021-00819-1
EJNMMI Research
Miller, C G, Grønbæk, H, Virgolini, I, Kjaer, A, Terve, P, Bahri, S, Iversen, P, Svirydenka, H, Rohban, T & McEwan, S 2021, ' A novel read methodology to evaluate the optimal dose of 68 Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours : a phase II clinical trial ', EJNMMI Research, vol. 11, no. 1, 84, pp. 1-11 . https://doi.org/10.1186/s13550-021-00819-1
Miller, C G, Grønbæk, H, Virgolini, I, Kjaer, A, Terve, P, Bahri, S, Iversen, P, Svirydenka, H, Rohban, T & McEwan, S 2021, ' A novel read methodology to evaluate the optimal dose of 68 Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours : a phase II clinical trial ', EJNMMI research, vol. 11, no. 84, 84 . https://doi.org/10.1186/s13550-021-00819-1
Background 68Ga-satoreotide trizoxetan is a novel somatostatin receptor antagonist exhibiting higher tumour-to-background ratios and sensitivity compared to 68Ga-DOTATOC. This randomised, 2 × 3 factorial, phase II study aimed to confirm the optimal
Autor:
Guenther Brueggenwerth, Richard C. Walovitch, Colin G Miller, Klaus Noever, Robert Ford, David L. Raunig, Annette Schmid, Ivalina Hristova, Michael O'Neal, Michael O’Connor
Publikováno v:
Therapeutic Innovation & Regulatory Science. 55:1122-1138
Though many clinical trials rely on medical image evaluations for primary or key secondary endpoints, the methods to monitor reader performance are all too often mired in the legacy use of adjudication rates. If misused, this simple metric can be mis
Autor:
Colin G Miller, Liz Kuney, Michael O’Connor, Richard C. Walovitch, Annette Schmid, Robert W. Ford, Josy Breuer, Robert Ford, Guenther Brueggenwerth, David L. Raunig
Publikováno v:
Therapeutic Innovation & Regulatory Science
The debate over human visual perception and how medical images should be interpreted have persisted since X-rays were the only imaging technique available. Concerns over rates of disagreement between expert image readers are associated with much of t